GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
First Quarter 2018 Financial Results to be Announced May 8, 2018
Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials
CAMBRIDGE, Mass., May 01, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report the company’s first quarter 2018 financial results on Tuesday, May 8, 2018.
Epizyme also plans to host a conference call and webcast for investors on the morning of May 17, 2018 to discuss recent corporate updates and new tazemetostat clinical data that will be included in upcoming medical meeting abstracts. Details for this call will be provided in the company’s May 8 press release.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Contacts
Media:
Cheya Pope, Epizyme, Inc.
[email protected]
(617) 229-7561
Investors:
Jason Fredette, Epizyme, Inc.
[email protected]
(617) 500-0623
